Candel Therapeutics, Inc. (CADL)
11.47
-0.70
(-5.75%)
USD |
NASDAQ |
Sep 10, 13:28
Candel Therapeutics Shareholders Equity (Quarterly) : 126.13M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 126.13M |
| March 31, 2026 | 138.03M |
| December 31, 2025 | 51.92M |
| September 30, 2025 | 80.12M |
| June 30, 2025 | 90.21M |
| March 31, 2025 | 74.68M |
| December 31, 2024 | 66.33M |
| September 30, 2024 | -15.26M |
| June 30, 2024 | -9.972M |
| March 31, 2024 | 5.979M |
| December 31, 2023 | 12.74M |
| September 30, 2023 | 23.02M |
| Date | Value |
|---|---|
| June 30, 2023 | 30.77M |
| March 31, 2023 | 39.65M |
| December 31, 2022 | 47.71M |
| September 30, 2022 | 52.13M |
| June 30, 2022 | 60.07M |
| March 31, 2022 | 63.76M |
| December 31, 2021 | 64.14M |
| September 30, 2021 | 62.99M |
| June 30, 2021 | 5.885M |
| March 31, 2021 | 21.56M |
| December 31, 2020 | 25.50M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 208.15M |
| Total Liabilities (Quarterly) | 82.02M |
| Debt to Equity Ratio | 0.3926 |
| Current Ratio | 16.09 |
| Net Debt Paydown Yield | -0.98% |